Stockscreener 앱 받기
26.11
12.20%
2.84
시간 외 거래:
26.11
전일 마감가:
$23.27
열려 있는:
$23.27
하루 거래량:
1.67M
Relative Volume:
2.32
시가총액:
$1.40B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+24.27%
1개월 성능:
+32.00%
6개월 성능:
+64.21%
1년 성능:
+262.14%
1일 변동 폭
$23.01
$27.24
1주일 범위
$20.56
$27.24
52주 변동 폭
$6.11
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
명칭
Zenas Biopharma Inc
전화
857-271-2954
주소
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
26.11 | 1.25B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 개시 | Wedbush | Outperform |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-16 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Nigeria
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - Bluefield Daily Telegraph
Zenas BioPharma Announces Late-Breaking Platform - GlobeNewswire
Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm
Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq
Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
A Big Boss Bet on Zenas BioPharma’s Future - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys 57,000 Shares - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 8.9%Here's Why - MarketBeat
Chipmakers Recap: What is the target price for Zenas BioPharma Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - GlobeNewswire Inc.
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 27.4% in January - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Published on: 2026-02-01 19:33:40 - baoquankhu1.vn
Investment Report: What are analysts price targets for ArrowMark Financial CorpWeekly Investment Summary & Daily Stock Momentum Reports - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Is Zenas BioPharma Inc.’s growth already priced in2025 Top Gainers & Safe Entry Trade Reports - mfd.ru
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - Chartmill
Zenas BioPharma Slams Investor's Revamped Fraud Claim - Law360
Can Zenas BioPharma Inc be the next market leaderOptions Play & Short-Term High Return Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma (ZBIO) Stock Analysis: Promising 99.75% Upside Potential For Investors - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPhar - The National Law Review
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 6.6%Here's Why - MarketBeat
Zenas Bio rises as Wedbush launches with Outperform on lead asset - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Robbins LLP Reminds ZBIO Stockholders with Large Losses to Contac - The National Law Review
Zenas BioPharma Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Zenas crashes as late-stage trial data for lead asset disappoint - MSN
Portfolio Update: Will Zenas BioPharma Inc outperform during market ralliesWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Moving Averages: Can Northann Corp navigate macro headwindsPortfolio Return Summary & Comprehensive Market Scan Reports - baoquankhu1.vn
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1%Time to Sell? - MarketBeat
Zenas BioPharma Stock Pre-Market (-4.4%): Shareholder Lawsuit Investigation Announced - Trefis
Assessing Zenas BioPharma (ZBIO) Valuation After Phase 3 INDIGO Success And CEO Share Purchase - Sahm
Zenas Biopharma Inc (ZBIO) 재무 분석
Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Zenas Biopharma Inc 주식 (ZBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Jan 07 '26 |
Buy |
16.38 |
50,000 |
819,000 |
316,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 08 '26 |
Buy |
16.30 |
30,000 |
489,000 |
346,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 09 '26 |
Buy |
16.55 |
20,000 |
331,000 |
366,155 |
| Nunn Jason Raleigh | Director |
Oct 09 '25 |
Buy |
19.00 |
63,158 |
1,200,002 |
1,173,395 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
| MOULDER LEON O JR | See Remarks |
Oct 07 '25 |
Buy |
20.85 |
36,928 |
769,949 |
36,928 |
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
1.24%
0.19%
자본화:
|
볼륨(24시간):